Literature DB >> 18005040

Does propofol and alfentanil-induced sedation cause periodic apnoea in chronic renal failure patients?

S M Lee1, G H Kim, J J Lee, J A Kim, S J Choi, G S Kim, H H Jung.   

Abstract

AIMS: There is evidence suggesting that the respiratory response to sedation is different in patients with sleep apnoea, which is common in patients with chronic renal failure (CRF). This study examined the respiratory response of sedation with propofol and alfentanil, whose pharmacokinetics are not affected by the renal function, in CRF patients.
METHODS: Chronic renal failure patients who underwent arteriovenous-fistular surgery (CRF group) and patients who underwent chemoport insertion (control group) were enrolled in this study. Sedation was induced by infusing propofol 1.5 micro/ml and alfentanil 0.2 micro/kg/min continuously in both groups. In the desaturation study, the respiratory rate and peripheral oxygen saturation in room air were checked. In the apnoea-hypopnoea study, the patient's sedation (Observer's Assessment of Alertness/Sedation) score, apnoea-hypopnoea index (AHI) was recorded using a portable ventilation effort recorder (microMesam) while applying 5 l/min of oxygen through a facial mask.
RESULTS: The desaturation event was more common (21.5/h vs. 2/h, p = 0.001) in the CRF patients. Apnoea and hypopnoea (AHI: 13.0 vs. 1.6, p = 0.012, per cent of patients with an AHI > 5: 53.3% vs. 7.1%, p = 0.014) occurred more frequently in the CRF patients but the sedation score was not different.
CONCLUSION: Chronic renal failure patients have a higher risk of developing apnoea and hypopnoea during sedation, which highlights the need for careful monitoring and management in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005040     DOI: 10.1111/j.1742-1241.2007.01443.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  1 in total

1.  Efficacy of liraglutide in a real-life cohort.

Authors:  Anthony Heymann; Yasmin Maor; Inbal Goldstein; Lora Todorova; Perlit Schertz-Sternberg; Avraham Karasik
Journal:  Diabetes Ther       Date:  2014-03-25       Impact factor: 2.945

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.